Company Sarepta Therapeutics, Inc.

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 06/12/2025 am IST			5-day change	1st Jan Change
22.26 ^USD	-2.45%		+4.31%	-81.69%

25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
25/11	Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy	MT

Business description: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Number of employees: 1,372

Sales by Activity: Sarepta Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovering, Developing, Manufacturing and Delivering Therapies	54Cr	70Cr	93Cr	124.33Cr	190.2Cr

See all business segments

Geographical breakdown of sales: Sarepta Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	54Cr	70Cr	93Cr	124.33Cr	190.2Cr

See all geographic segments

Executive Committee: Sarepta Therapeutics, Inc.

Manager	Title	Age	Since
Douglas Ingram CEO	Chief Executive Officer	62	26/06/2017
Ryan Wong DFI	Director of Finance/CFO	46	16/07/2025
Ian Estepan DFI	Director of Finance/CFO	49	14/12/2020
Louise Rodino-Klapac CTO	Chief Tech/Sci/R&D Officer	47	14/12/2020
Alison Nasisi HRO	Human Resources Officer	-	01/10/2021

See SAREPTA THERAPEUTICS, INC. governance

Composition of the Board of Directors: Sarepta Therapeutics, Inc.

Director	Title	Age	Since
M. Wilsey CHM	Chairman	72	16/04/2015
Hans Lennart Rudolf Wigzell BRD	Director/Board Member	86	01/06/2010
Richard Barry BRD	Director/Board Member	66	02/06/2015
Claude Nicaise BRD	Director/Board Member	72	02/06/2015
Stephen Mayo BRD	Director/Board Member	63	16/11/2021
Michael Chambers BRD	Director/Board Member	50	02/06/2022
Kathryn Boor BRD	Director/Board Member	66	02/06/2022
Deirdre Connelly BRD	Director/Board Member	64	12/09/2024

Composition of the Board of Directors

Shareholders: Sarepta Therapeutics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 12.56 %	1,22,68,476	12.56 %	295 M $
Vanguard Fiduciary Trust Co. 11.07 %	1,08,17,446	11.07 %	260 M $
STATE STREET CORPORATION 5.429 %	53,04,907	5.429 %	127 M $
Richard Barry 3.292 %	32,16,667	3.292 %	77 M $
Erste Asset Management GmbH 2.749 %	26,85,945	2.749 %	64 M $

List of SAREPTA THERAPEUTICS, INC. shareholders

Company details: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

215 First Street

02142, Cambridge

+617 274 4000

http://www.sarepta.com

address Sarepta Therapeutics, Inc.(SRPT)

Diagnostic & Testing Substances Manufacturers

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SAREPTA THERAPEUTICS, INC.	-2.45%	+4.31%	-82.63%	-81.47%	233.26Cr
ULTRAGENYX PHARMACEUTICAL INC.	-0.44%	+4.69%	-26.33%	-7.24%	350.36Cr
BIONOTE, INC.	+0.89%	0.00%	+22.61%	-	39Cr
DK LIFE SCIENCE CO., LTD.	-0.65%	+2.40%	-	-	8.35Cr
Average	-0.66%	+2.47%	-28.78%	-44.35%	157.69Cr
Weighted average by Cap.	-1.10%	+4.23%	-44.38%	-36.91%